0.00%
0.06%
2.20%
7.31%
2.23%
-35.18%
-42.00%
AI Spotlight on ATRI
Company Description
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally.Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.
Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults.The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment.In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications.
The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors.Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Market Data
| Last Price | 459.92 |
| Change Percentage | 0.06% |
| Open | 459.75 |
| Previous Close | 459.66 |
| Market Cap ( Millions) | 809 |
| Volume | 29517 |
| Year High | 503.24 |
| Year Low | 274.98 |
| M A 50 | 455.95 |
| M A 200 | 400.15 |
Financial Ratios
| FCF Yield | 3.42% |
| Dividend Yield | 0.96% |
| ROE | 5.21% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -38.72% |
| Price To Book | 3.39 |
| Price Earnings Ratio | 64.5 |
| Price To FCF | 29.24 |
| Price To sales | 4.46 |
| EV / EBITDA | 26.95 |
News
- Aug -14 - Smaller But Mighty: 3 Small-Cap Stocks for Long-Term Dividend Growth
- Aug -09 - Atrion's (ATRI) Q2 Earnings Plummet Y/Y on Nordson Merger Costs
- Aug -08 - Atrion Reports Second Quarter 2024 Results
- Jul -29 - ATRI ALERT: The M&A Class Action Firm Investigates the Merger and August 19, 2024 Shareholder Vote of Atrion Corporation
- Jul -28 - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders
- Jul -17 - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGR, SHCR on Behalf of Shareholders
- Jul -16 - STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. – SILK
- Jul -15 - STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Silk Road Medical, Inc. - SILK
- Jul -08 - STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX
- Jul -03 - URGENT SHAREHOLDER UPDATE: The M&A Class Action Firm Investigates Merger and Incoming Vote on July 30, 2024, of Perficient, Inc. - PRFT
- Jun -07 - Zacks Initiates Coverage of Atrion With Neutral Recommendation
- May -28 - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Atrion Corporation
- May -28 - Shareholder Alert: Ademi LLP investigates whether Atrion Corporation has obtained a Fair Price for its Public Shareholders in its transaction with Nordson
- May -28 - ATRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Atrion Corporation Is Fair to Shareholders
- May -28 - Atrion Corporation Enters Into Merger Agreement with Nordson Corporation
- May -28 - Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies
- May -21 - Atrion Corporation Declares Quarterly Cash Dividend
- May -10 - Atrion Reports First Quarter 2024 Results
- Feb -29 - Atrion Reports Fourth Quarter And Full Year 2023 Results
- Feb -27 - Atrion Corporation Declares Quarterly Cash Dividend
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Fluid Delivery
Expected Growth : 4.8 %
What the company do ?
Fluid Delivery from Atrion Corporation refers to a medical device that delivers fluids, such as saline or medications, to patients through an IV system.
Why we expect these perspectives ?
The fluid delivery market is driven by the increasing demand for IV systems, advancements in medical technology, and the growing need for efficient fluid delivery systems in hospitals and clinics.
Segment n°2 -> Cardiovascular
Expected Growth : 7.8 %
What the company do ?
Atrion Corporation's Cardiovascular segment offers medical devices and components used in cardiovascular procedures, including vascular grafts, stents, and catheters.
Why we expect these perspectives ?
Growing demand for minimally invasive procedures, increasing prevalence of cardiovascular diseases, and advancements in medical technology drive the growth of Atrion's Cardiovascular segment.
Segment n°3 -> Other
Expected Growth : 4.5 %
What the company do ?
Atrion Corporation's 'Other' segment includes the company's minority interest in a joint venture and other miscellaneous investments.
Why we expect these perspectives ?
Atrion's 'Other' segment, comprising minority interest in a joint venture and miscellaneous investments, is expected to grow steadily driven by increasing demand for diversified investments and strategic partnerships.
Segment n°4 -> Ophthalmology
Expected Growth : 6.5 %
What the company do ?
Ophthalmology from Atrion Corporation refers to the branch of medicine dealing with the diagnosis, treatment, and surgery of eye disorders and diseases.
Why we expect these perspectives ?
Increasing prevalence of eye disorders, advancements in ophthalmic technologies, and growing demand for minimally invasive surgeries drive the ophthalmology market growth.
Atrion Corporation Products
| Product Range | What is it ? |
|---|---|
| Network Infrastructure Solutions | Atrion Corporation provides network infrastructure solutions that enable organizations to design, implement, and manage their network infrastructure efficiently. |
| Cybersecurity Services | Atrion Corporation offers cybersecurity services that help organizations protect themselves from cyber threats and vulnerabilities. |
| Unified Communications Solutions | Atrion Corporation provides unified communications solutions that enable organizations to collaborate and communicate effectively. |
| Cloud and Managed Services | Atrion Corporation offers cloud and managed services that help organizations migrate and manage their IT infrastructure in the cloud. |
| IT Consulting Services | Atrion Corporation provides IT consulting services that help organizations assess, design, and implement IT solutions that meet their business needs. |
Atrion Corporation's Porter Forces
Threat Of Substitutes
Atrion Corporation faces moderate threat from substitutes due to the availability of alternative products in the market.
Bargaining Power Of Customers
Atrion Corporation has a diverse customer base, which reduces the bargaining power of individual customers.
Bargaining Power Of Suppliers
Atrion Corporation relies on a few key suppliers, which gives them significant bargaining power.
Threat Of New Entrants
Atrion Corporation operates in a capital-intensive industry, which creates a barrier to entry for new entrants.
Intensity Of Rivalry
Atrion Corporation operates in a highly competitive industry, which leads to intense rivalry among existing players.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.10% |
| Debt Cost | 7.06% |
| Equity Weight | 99.90% |
| Equity Cost | 7.06% |
| WACC | 7.06% |
| Leverage | 0.10% |
Atrion Corporation : Quality Control
Atrion Corporation passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| NXGL | NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The … |
| INFU | InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) … |
| HBIO | Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company … |
| FEMY | Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination … |
| STAA | STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Atrion
A-Score
1-Year Total Return ->
🥈
NEXGEL
A-Score
1-Year Total Return ->
🥉
STAAR Surgical
A-Score
1-Year Total Return ->
4
InfuSystem Holdings
A-Score
1-Year Total Return ->
5
Femasys
A-Score
1-Year Total Return ->
6
